Insulin glargine: a long-acting insulin for diabetes mellitus.
Copyright policy )Insulin glargine: a long-acting insulin for diabetes mellitus.
Insulin glargine is a once-daily, biosynthetic, human insulin analogue. Some trials show that in patients with type 1 diabetes mellitus, insulin glargine offers an advantage in blood glucose control compared with NPH insulin. There is some evidence of decreased nocturnal and symptomatic hypoglycemia in patients receiving insulin glargine compared with those receiving NPH insulin, but there are no significant differences in the incidence of severe hypoglycemia. Insulin glargine is approved for use in Canada, but it has not yet been marketed.
Canada, Clinical Trials as Topic, Injections, Subcutaneous, Drug Administration Schedule, Drug Costs, Diabetes Mellitus, Type 1, Treatment Outcome, Humans, Hypoglycemic Agents, Insulin, Drug Approval, Randomized Controlled Trials as Topic
Canada, Clinical Trials as Topic, Injections, Subcutaneous, Drug Administration Schedule, Drug Costs, Diabetes Mellitus, Type 1, Treatment Outcome, Humans, Hypoglycemic Agents, Insulin, Drug Approval, Randomized Controlled Trials as Topic
citations The total number of citations received by all articles of the researcher of interest.0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!